Search Results
Your search for it matches 15885 pages
Showing 51 - 100Primary Analysis Shows Survival Benefit With Bemarituzumab Plus Chemotherapy in Gastric or Gastroesophageal Junction Cancer
The addition of bemarituzumab, a first-in-class anti-FGFR2b antibody, to mFOLFOX6 chemotherapy significantly improved overall survival in patients with FGFR2b-overexpressing (≥ 10% tumor cell staining) unresectable, locally advanced or metastatic gastric or gastroesophageal junction cancer,...
Final Analysis Supports Use of Durvalumab Plus BCG Infusions in High-Risk Non–Muscle-Invasive Bladder Cancer
In patients with high-risk non–muscle-invasive bladder cancer, the addition of 1 year of the PD-L1 inhibitor durvalumab to standard induction and maintenance bacillus Calmette-Guérin (BCG) infusions led to a statistically significant and clinically meaningful improvement in disease-free survival...
Ivonescimab, a Dual-Targeting Bispecific Antibody, Improves Progression-Free Survival in Squamous NSCLC
In the phase III HARMONi-6 trial, conducted in China, the bispecific antibody ivonescimab, given with chemotherapy, improved progression-free survival by 4.2 months over the PD-1 inhibitor tislelizumab-jsgr plus chemotherapy, a 40% reduction in risk as first-line treatment of advanced squamous...
European Society for Medical Oncology Congress 2025 Meeting Highlights
The European Society for Medical Oncology (ESMO) Congress 2025 in Berlin featured many important trials with the potential to significantly influence clinical practice and improve outcomes for patients with multiple tumor types. These studies highlighted the benefits of novel treatment combination...
ASTRO Publishes First Clinical Guideline on Radiation Therapy for Gastric Cancer
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) is the first to focus on radiation therapy for patients with gastric cancer. The recommendations outline radiation therapy’s role in multidisciplinary care, including best practices for patient selection, integration...
Pembrolizumab Plus Weekly Paclitaxel Improves Survival Outcomes in Platinum-Resistant Recurrent Ovarian Cancer
The addition of the PD-1 inhibitor pembrolizumab to weekly paclitaxel, with or without the VEGFA-targeted bevacizumab, significantly improved progression-free survival and overall survival in patients with platinum-resistant recurrent ovarian cancer, in the randomized, double-blind, phase III...
HER2-Positive Early Breast Cancer: Trastuzumab Deruxtecan Moves Into Earlier Clinical Settings
Two pivotal studies of fam-trastuzumab deruxtecan-nxki (T-DXd) in early HER2-positive breast cancer suggest this antibody-drug conjugate (targeting the HER2 protein) may be moving into the curative setting after having shown benefit in metastatic disease in multiple previous trials. The new...
Perioperative Immunotherapy Regimen Improves Outcomes in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
A perioperative regimen of the antibody-drug conjugate enfortumab vedotin-ejfv plus the PD-1 inhibitor pembrolizumab significantly improved outcomes vs radical cystectomy alone in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin-based chemotherapy. Results...
Geriatric Assessment–Guided Approach to Treatment Intensity in Older Adults With Acute Myeloid Leukemia
“Pretreatment geriatric assessment in older adults with acute myeloid leukemia is feasible, can identify several functional impairments, and [can] guide the selection of treatment intensity,” resulting in low rates of early mortality, according to Vijaya R. Bhatt, MBBS, MS, of the University of...
Reducing the Barriers to Receiving CAR T-Cell Therapy for Patients With Hematologic Malignancies
Chimeric antigen receptor (CAR) T-cell therapy has transformed treatment for patients with hematologic malignancies, achieving unprecedented responses in some patients, especially those diagnosed with relapsed/refractory B-cell acute lymphocytic leukemia, non-Hodgkin lymphoma, and multiple...
ASTRO Experts Comment on the Results of the SUPREMO Trial
A large international study published by Kunkler et al in The New England Journal of Medicine examined whether chest wall radiation therapy after mastectomy improves survival for patients with early-stage breast cancer. The study, known as the SUPREMO trial, found no overall survival difference...
Could Opportunistic Salpingectomy Prevent Ovarian Cancer in Postreproductive Women?
Known as “the silent killer” due to its lack of symptoms and reliable screening tests, ovarian cancer remains one of the deadliest gynecologic cancers, claiming more than 12,000 lives annually. At a recent meeting, experts said that performing a single preventive procedure within general surgery...
Patient Immune System Characteristics and Long-Term Remission From CAR T-Cell Therapy in Multiple Myeloma
Patients with relapsed or refractory multiple myeloma who achieve a long-lasting disease remission from chimeric antigen receptor (CAR) T-cell therapy may differ from patients who relapse sooner based upon their immune system and how it responds to the infused CAR T cells, as well as how it...
New Computational Tool Shows Strong Accuracy in Predicting Cancer Drug Targets
Using a computational tool, DeepTarget, physicians were able to predict both primary and secondary targets of small-molecule agents for cancer treatment, according to findings from a study published in npj Precision Oncology. The study authors suggest that this represents a potentially significant...
Curative Treatment After First-Line Immunotherapy Improves Survival in HCC
Curative treatment following first-line immunotherapy is infrequently received, but when it was utilized, it significantly improved overall survival outcomes for patients with hepatocellular carcinoma, according to findings from a study published in Liver Cancer. The risk for death was improved by...
New Study Explores Why Male Patients With AML May Have Worse Outcomes
New research has ruled out hormone signaling as the reason why men with acute myeloid leukemia (AML) tend to have poorer outcomes than women, even when treated with the same intensive chemotherapy—a finding that helps refine future research and could influence clinical trial design. The...
More Patients With Cancer Are Using Crowdfunding to Pay for Care—and Coming up Short
Studies show that cancer is one of the leading diseases among all medical crowdfunding campaigns, with GoFundMe being the most popular platform for peer-to-peer medical donations. A new study by researchers at the American Cancer Society (ACS) has found that a growing number of cancer survivors are ...
Pancreatic Cancer: Mild Duct Dilation May Serve as Early Indicator in High-Risk Patients
Mild dilation of the main pancreatic duct without an apparent obstructing mass may be an independent risk factor for neoplastic progression to pancreatic cancer in high-risk individuals, according to findings from an analysis published in Gastro Hep Advances. “We are identifying pancreas duct...
Survey Highlights Unmet Needs Among Young Women With Advanced Breast Cancer
Almost half of all women (48%) under the age of 40 who are living with advanced breast cancer have children under the age of 18, and 64% of these young patients also experience employment disruptions after they are diagnosed, according to findings from a survey conducted by the Young Survival...
Global Report Highlights Decade of Uneven Progress in Advanced Breast Cancer Care
ABC Global Alliance's landmark Advanced Breast Cancer Global Decade Report 2015–2025 was recently released and published in The Breast. The report highlights significant advancements made over the past decade that have transformed care for patients with advanced breast cancer, but also reveals gaps ...
Study Finds Gaps Exist in Quality of Cancer Care for Incarcerated People
In the United States, the incarcerated population is aging. About 15% of incarcerated adults, or approximately 175,000 people, are now 55 years or older. As the incarcerated population ages, cancer has become one of the greatest threats to their health. And despite the growing prevalence, cancer...
Armando E. Giuliano, MD, To Be Honored With 2025 William L. McGuire Memorial Lecture Award at SABCS
Armando E. Giuliano, MD, will receive the William L. McGuire Memorial Lecture Award during the 2025 San Antonio Breast Cancer Symposium (SABCS). Dr. Giuliano is being recognized for his pioneering work on sentinel lymph node biopsy for patients with breast cancer, which has transformed the...
ASCO and ONS Issue First Collaborative Guideline on Extravasation
ASCO and the Oncology Nursing Society (ONS) have released their first joint guideline on managing extravasation, an uncommon but potentially life-threatening complication of intravenous antineoplastic therapy.1 Extravasation occurs when an agent with tissue-damaging properties leaks from the...
Making Clinical Trials More Accessible: New Report Highlights Barriers and Solutions
Clinical trials remain out of reach for many Americans, with only 7% of patients with cancer participating in clinical trials, according to a new report from the American Society of Clinical Oncology’s (ASCO) State of Cancer Care in America series. Experts agree that access to trials is a key...
Reducing the Impact of Climate-Induced Events on Patients and Oncology Staff
Although 2023 made headlines as the hottest year in human history,1 drawing the world closer to breaching the goals outlined in the Paris Agreement to substantially reduce global greenhouse gas emissions to limit global warming to well below 2°C above preindustrial levels (and preferably to...
Immunotherapy Combination Active in Patients With Large B-Cell Lymphoma Who Are Not Eligible for Autologous Stem Cell Transplant
In the global phase III SUNMO trial, the combination of a bispecific antibody and an antibody-drug conjugate was compared with rituximab plus gemcitabine and oxaliplatin (GemOx) in the treatment of patients with relapsed or refractory large B-cell lymphoma (LBCL) who were ineligible for autologous...
Safety and Benefit of Radiation Therapy for High-Risk Muscle-Invasive Bladder Cancer
Following cystectomy, patients with muscle-invasive bladder cancer at high risk for recurrence may safely be treated with radiotherapy and may achieve an improvement in locoregional control compared with observation. These findings, which come from the phase III BART trial presented in a plenary...
Intensity-Modulated Radiation Therapy vs Proton Therapy for Oropharyngeal Cancer
The phase III TORPEdO trial reported no meaningful differences between intensity-modulated radiation therapy (IMRT) and proton beam therapy at 1 year in terms of patient-reported quality of life, swallowing function, or feeding tube dependence for individuals with locally advanced oropharyngeal...
Impact of Concomitant Noncancer Medications on Outcomes in Breast Cancer
An evaluation of noncancer medications used concomitantly with cancer therapies for patients with breast cancer showed that proton pump inhibitors specifically were associated with worse survival outcomes and with an increased risk of grade 3 or higher adverse events than other classes of therapy....
Adding an Investigational Monoclonal Antibody to Ibrutinib May Allow Patients With CLL to Discontinue Daily Treatment
Chronic lymphocytic leukemia (CLL) is the most prevalent type of leukemia in the Western hemisphere, accounting for between 25% and 35% of all leukemias in the United States. According to the American Cancer Society, nearly 24,000 new cases of CLL will be diagnosed in the United States this year,...
FDA Approves Daratumumab and Hyaluronidase-fihj for High-Risk Smoldering Multiple Myeloma
On November 6, 2025, the U.S. Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) for adults with high-risk smoldering multiple myeloma. Efficacy of daratumumab and hyaluronidase as monotherapy vs active monitoring was evaluated in AQUILA, an open-label,...
A Serendipitous Fall May Have Saved My Life
In the spring of 2024, I was preparing to compete in a Half Ironman triathlon and was not surprised when I began experiencing tightness in my groin. I just figured it was the byproduct of specific endurance training I was doing in each discipline, including running, biking, and swimming, to get...
Physician-Complementing Artificial Intelligence in Oncology
Use of artificial intelligence (AI) in oncology is advancing rapidly. AI was first used for reading radiology images and analyzing pathology slides. More recently, use of AI has expanded to analyzing large clinical data sets (big data). The next envisioned role for AI in oncology encompasses many ...
Basser Center for BRCA Announces Two Award Winners
The Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania, the world’s first comprehensive center aimed at advancing research, treatment, and prevention of BRCA-related cancers, is honoring Alan D. D'Andrea, MD, of Dana-Farber Cancer Institute, with the 2025 BRCA...
Final Overall Survival Confirms Benefit of Durvalumab Plus FLOT in Resectable Gastric and Gastroesophageal Junction Adenocarcinomas
The addition of the PD-L1–targeting monoclonal antibody durvalumab to conventional perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) resulted in a statistically significant and clinically meaningful improvement in overall survival, with benefit seen...
New Report: Lung Cancer Advancements Are Saving More Lives Than Ever, but Funding Cuts May Hinder Progress
The American Lung Association has released its 2025 “State of Lung Cancer” report, which reveals great strides in efforts to end lung cancer—the leading cause of cancer-related deaths in the United States. This year, nearly 227,000 people in the United States will be diagnosed with lung cancer....
Study Finds Breast Cancer Risk Varies Between Different Hormonal Contraceptives
Some common hormonal contraceptives are linked to a slightly higher risk of breast cancer than others. This is shown by a new study from Uppsala University, in which researchers followed more than 2 million women and teenage girls in Sweden to identify how different hormonal contraceptives affect...
Diminishing the National Cancer Institute Threatens Americans
In an effort to reduce the size of government, the current administration has proposed an across the board 37% reduction1 in funding for the National Cancer Institute (NCI). This will result in approval of only 4% of applications2 from scientists at universities and cancer centers, with 96% of all ...
Experts Outline Roadmap for Clinical Implementation of AI in Pediatric CNS Tumor Management
A subcommittee of the RAPNO (Response Assessment in Pediatric Neuro-Oncology) consortium that is focused on artificial intelligence (AI-RAPNO) has released guidance on the responsible implementation of AI in pediatric neuro-oncology in the form of a two-part policy review published in The Lancet...
Reflections of a Medical Oncologist: Empathy Matters in Caring for Patients With Cancer
“Someday you will be a doctor, Fazlur, and help people,” were the prophetic words of a mother to her son and the driving force behind the early quest of Fazlur Rahman, MD, to become a physician. Born and raised in what is now Bangladesh, he experienced the death of his mother at the young age of ...
Pembrolizumab Plus Weekly Paclitaxel Improves Survival Outcomes in Platinum-Resistant Recurrent Ovarian Cancer
The addition of the PD-1 inhibitor pembrolizumab to weekly paclitaxel, with or without the VEGFA-targeted bevacizumab, significantly improved progression-free survival and overall survival in patients with platinum-resistant recurrent ovarian cancer, in the randomized, double-blind, phase III...
My 50 Years in Lymphoma: Lessons Learned?
In the 50 years now since my fellowship training, there have been major advances in the diagnosis, staging, prognostic scoring, treatment, and response assessment of lymphomas. To conjure up the future, we must first appreciate the present by understanding how it arose from the past.1 So, a trip in ...
Global Analysis Uncovers Wide Inequalities in Care for Breast, Cervical, and Ovarian Cancers
A major study of three of the most common cancers in women, conducted by the Cancer Survival Group at the London School of Hygiene & Tropical Medicine, found variations in the stage of disease at diagnosis, the type of treatment, and the extent to which treatment was consistent with...
Cancer Data Scientist Joins Translational Research Institute at Cedars-Sinai
Eytan Ruppin, MD, PhD, has been appointed Deputy Director of the Translational Research Institute as well as Director of Integrative Data Sciences in the Division of Surgical Research at Cedars-Sinai Cancer. “We are delighted to welcome Dr. Ruppin to Cedars-Sinai as a prestigious senior scientist ...
Testing for Melanoma Sentinel Lymph Node Status
A gene expression profile–based test coupled with clinicopathologic factor assessment was able to consistently identify patients with melanoma who were at a low risk for their disease spreading to the sentinel lymph nodes, according to findings from the MERLIN_001 trial published in JAMA Surgery....
Preneoplastic and Neoplastic Small Lymphocytic Proliferations
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD, explore the key epidemiologic, pathologic, diagnostic, and prognostic aspects of chronic...
Zenocutuzumab Potential Explored in NRG1-Positive Cholangiocarcinoma
Zenocutuzumab-zbco yielded clinical activity in more than one-third of patients with cholangiocarcinoma and an NRG1 fusion, according to findings from the phase II eNRGy trial presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Abstract ...
Physician-Complementing Artificial Intelligence in Oncology
Use of artificial intelligence (AI) in oncology is advancing rapidly. AI was first used for reading radiology images and analyzing pathology slides. More recently, use of AI has expanded to analyzing large clinical data sets (big data). The next envisioned role for AI in oncology encompasses many ...
Elironrasib Active in KRAS G12C–Resistant NSCLC
Elironrasib, a novel RAS G12C–selective tri-complex inhibitor, demonstrated initial clinical activity and a differentiated safety profile in heavily pretreated patients with non–small cell lung cancer (NSCLC) and KRAS G12C mutations, according to findings from a phase I trial presented at the 2025...
HER2-Positive Early Breast Cancer: Trastuzumab Deruxtecan Moves Into Earlier Clinical Settings
Two pivotal studies of fam-trastuzumab deruxtecan-nxki (T-DXd) in early HER2-positive breast cancer suggest this antibody-drug conjugate (targeting the HER2 protein) may be moving into the curative setting after having shown benefit in metastatic disease in multiple previous trials. The new...
